(E)-1-(2,4-dimethoxyphenyl)-3-(2-nitrophenyl)-2-propen-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-1-(2,4-dimethoxyphenyl)-3-(2-nitrophenyl)-2-propen-1-one
• 英文别名: (E)-1-(2,4-dimethoxyphenyl)-3-(2-nitrophenyl)prop-2-en-1-one；1-(2,4-dimethoxy-phenyl)-3-(2-nitro-phenyl)-propenone
• 化学式: C₁₇H₁₅NO₅
• 分子量: 313.31
• InChiKey: PAMHHVLOPQSNFE-JXMROGBWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  81.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-1-(2,4-dimethoxyphenyl)-3-(2-nitrophenyl)-2-propen-1-one 在 盐酸 、 铁粉 作用下， 以 乙醇 、 水 为溶剂， 生成 2-(2,4-dimethoxyphenyl)quinoline
  参考文献：
  名称：

  通过可扩展的串联光异构化-环化过程连续合成喹啉

  摘要：

  据报道，利用光驱动方法的连续流动过程产生了一系列药物样喹啉，并将其应用于生物碱天然产物加利普宁的合成。

  DOI：

  10.1002/ejoc.202000957
• 作为产物：
  描述：

  2,4-二甲氧基苯乙酮 、 邻硝基苯甲醛 在 sodium hydroxide 作用下， 以 乙醇 、 水 、 乙腈 为溶剂， 反应 1.0h， 以84%的产率得到(E)-1-(2,4-dimethoxyphenyl)-3-(2-nitrophenyl)-2-propen-1-one
  参考文献：
  名称：

  通过可扩展的串联光异构化-环化过程连续合成喹啉

  摘要：

  据报道，利用光驱动方法的连续流动过程产生了一系列药物样喹啉，并将其应用于生物碱天然产物加利普宁的合成。

  DOI：

  10.1002/ejoc.202000957

文献信息

• [EN] NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER<br/>[FR] MODULATEURS DE RÉCEPTEURS NUCLÉAIRES ET LEUR UTILISATION POUR LE TRAITEMENT ET LA PRÉVENTION D'UN CANCER
  申请人：US HEALTH

  公开号：WO2012174436A1

  公开（公告）日：2012-12-20

  Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

  本文披露了一些化合物，它们是核受体调节剂，可以作为雄激素受体的拮抗剂，例如，公式I的化合物：其中R1至R5和X1至X5如本文所述，以及其药用盐、溶剂化合物和立体异构体。还披露了包括这些化合物的药物组合物，以及使用方法和治疗癌症，包括前列腺癌、其他核受体介导的癌症和其他疾病的方法。
• Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto
  申请人：Sperandio Vanessa

  公开号：US20100048573A1

  公开（公告）日：2010-02-25

  The present invention relates to compounds and methods for the treatment of bacterial infections. Because their mechanism of action does not involve killing of bacteria or inhibiting their growth, the potential for these compounds to induce drug resistance in bacteria is minimized. Through inhibiting bacterial virulence, the present invention provides a novel means of treating bacterial infections.

  本发明涉及化合物和方法，用于治疗细菌感染。由于它们的作用机制不涉及杀死细菌或抑制它们的生长，这些化合物诱导细菌耐药性的潜力被最小化。通过抑制细菌的毒力，本发明提供了治疗细菌感染的新方法。
• Total synthesis and assignment of the absolute stereochemistry of xanthoangelol J: development of a highly efficient method for Claisen–Schmidt condensation
  作者：Dwipen Kakati、Nabin C. Barua

  DOI：10.1016/j.tet.2013.11.106

  日期：2014.1

  The first total synthesis of cancer chemopreventive terpenyl hydroxychalcone xanthoangelol J isolated from Angelica keiskei was accomplished with asymmetric epoxidation, aromatic C-alkylation and Claisen-Schmidt condensation via enol mode as key steps. The crucial Claisen-Schmidt condensation has been accomplished by a novel green method using KHSO4-SiO2 as a recyclable catalyst under microwave activation. The absolute configuration of the molecule was also determined. (C) 2013 Elsevier Ltd. All rights reserved.
• A simple and highly efficient method for the synthesis of chalcones by using borontrifluoride-etherate
  作者：T. Narender、K. Papi Reddy

  DOI：10.1016/j.tetlet.2007.03.054

  日期：2007.4

  Chalcones are secondary metabolites of terrestrial plants, precursors for the biosynthesis of ilavonoids and exhibit various biological activities. Condensation of substituted acetophenones (2a-12a) with various aromatic aldehydes (1b-7b) in the presence of BF3-Et2O at room temperature gave chalcones in 75-96% yield. (c) 2007 Published by Elsevier Ltd.
• NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER
  申请人：Neckers Jane B.

  公开号：US20140171503A1

  公开（公告）日：2014-06-19

  Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R 1 to R 5 and X 1 to X 5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.